A Comprehensive and Comparative study of qualification process for Drug Development tools in US, Europe, Japan and India.

  • Garima Kshatriya Gujarat Technological University
  • Dilip G. Maheshwari

Abstract

Drug Development Tools are methods, materials, or measures that have the potential to facilitate drug development. USFDA has specified three major drug development tools and has also given the guidelines recommending their qualification which would expedite the drug development process. This qualification would ensure better understanding of drug targets and long term safety outcomes. Regulatory authorities of Europe, Japan & India have also focused on developing a formal qualification process of drug development tools though most of it follows USFDA.

Keywords: Drug Development Tools, Qualification, Regulations, Context of Use, Biomarkers, Clinical Outcome Assessment, Animal Models.

Downloads

Download data is not yet available.

References

1. U.S. Food and Drug Administration. Drug Development Tool Qualification Programme [Internet]. FDA; 2018 [Cited 2018 Jan 04] Available from:
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/
2. Strimbu K, Tavel JA. What are Biomarkers?, Current opinion in HIV and AIDS [Internet]. 2010 [Cited 2018 Jan 04]; 5(6). Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078627/
3. Ed Miseta, What You Need To Know About FDA's Clinical Outcome Assessment Compendium [Internet]. Clinical leader; 2016 Feb 08 [Cited 2018 Jan 06].Available from:
www.clinicalleader.com/doc/what-you-need-to-know-about-fda-s-clinical-outcome-assessment-compendium-0001
4. Committee on Animal Models for Assessing Counter measures to Bioterrorism Agents [Internet]. The National Academy Press; 2011 [Cited 2018 Jan 08]. Available from:
https://www.nap.edu/catalog/13233/animal-models-for-assessing-countermeasures-to-bioterrorism-agents
5. U.S. Department of Health and Human Services, Food and Drug Administration. Guidelines on Qualification Process of Drug Development Tools [Internet]. Center for Drug Evaluation and Research (CDER); 2014 Jan [Cited 2018 Jan 08]. Available from:
https://www.fda.gov/downloads/drugs/guidances/ucm230597.pdf
6. EMA. Qualification of novel methodologies for drug development: guidance to applicants [Internet]. EMEA; 2009 [Cited 2018 Jan 08]. Available from:
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004201.pdf
7. EMA. Reflection paper on methodological issues associated with pharmacogenomic biomarkers in relation to clinical development and patient selection [Internet]. EMEA; 2015 [Cited 2018 Jan 09]. Available from:
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/11/WC500196800.pdf
8. EMA. Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug development [Internet]. EMEA; 2010 [Cited 2018 Jan 09]. Available from:
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/07/WC500094445.pdf
9. EMA. Guideline on non-clinical local tolerance testing of medicinal products [Internet]. EMEA; 2015 [Cited 2018 Jan 10]. Available from:
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/11/WC500197321.pdf
10. Nieto-Gutierrez M. Non-clinical Assessment Requirements. Safety and Efficacy of Medicines/Human Medicines Development and Evaluation [Internet]. EMEA; 2011 [Cited 2018 Jan 10] Available from:
http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2011/06/WC500107868.pdf
11. ICH E 16: Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions [Internet].EMEA; 2009 [Cited 2018 Jan 10]. Available from:
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002881.pdf
12. Technical Guidance on Development of In Vitro Companion Diagnostics and Corresponding therapeutic Products [Internet]. [Cited 2018 Jan 10]. Available from:
file:///H:/data0/guidance-biomarker,%20JAPAN000 153149.pdf
13. Notification on Approval Application for In Vitro Companion Diagnostics and Corresponding Therapeutic Products [Internet]. PMDA; 2013 July 01[Cited 2018 Jan 10]. Available from:
https://www.pmda.go.jp/files/000153914.pdf
14. Kagiyama N, et.al. Japanese Guidelines & Regulations for Scientific & Ethical Animal Experimentation [Internet]. Japan: 2006 [Cited 2018 Jan 11]. Available from:
https://www.aaalac.org/intlRefs/IntRegs/Japan/Private%20site/Japanese_Guidelines.pdf
15. Omoe H. Recent Trends in Animal experimentation in Japan - On the Revision and Implementation of the Law for the Humane Treatment and Management of animals. [Internet]. Life Science Research Unit; 2006 Oct [Cited 2018 Jan 11]. Available from:
http://data.nistep.go.jp/dspace/bitstream/11035/2728/1/NISTEP-STT021E-13.pdf
16. Discussion paper. Workshop on Policy Issues for the Development and Use of Biomarkers in Health [Internet]. OECD; 2008 [Cited 2018 Jan 11]. Available from:
https://www.oecd.org/health/biotech/49023036.pdf
17. ICMR. Inserm Development of Biomarkers for CVD & Diabetes [Internet]. ICMR; 2007 [Cited 2018 Jan 12]. Available from:
www.icmr.nic.in/biomarkers/report.pdf
18. CPCSEA Guidelines For Laboratory Animal Facility, Committee for the Purpose of Control and Supervision on Experiments on Animals. Indian Journal of Pharmacology [Internet].2003 [Cited 2018 Jan 12]; 35:257-74. Available from:
http://medind.nic.in/ibi/t03/i4/ibit03i4p257.pdf
Statistics
181 Views | 312 Downloads
How to Cite
Kshatriya, G., and D. Maheshwari. “A Comprehensive and Comparative Study of Qualification Process for Drug Development Tools in US, Europe, Japan and India.”. International Journal of Drug Regulatory Affairs, Vol. 6, no. 2, June 2018, pp. 1-7, doi:https://doi.org/10.22270/ijdra.v6i2.227.